Protein misfolding detected early in pathogenesis of transgenic mouse model of huntington disease using amyloid seeding assay

Journal of Biological Chemistry

Volumn 287, Issue 13, 2012, Pages 9982-9989

  Gupta, Sharad ^a   Jie, Shy'Ann ^a   Colby, David W ^a  

^a University of Delaware   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER; AMYLOID FORMATION; BRAIN TISSUE; HUNTINGTIN; HUNTINGTON DISEASE; IN-VITRO; LAG PHASE; LARGE INCLUSIONS; MISFOLDED PROTEINS; MOUSE MODELS; NEURODEGENERATIVE DISORDERS; POLYGLUTAMINE; PRION DISEASE; PROTEIN MISFOLDING; SENSITIVE DETECTION; TRANSGENIC MICE; TRANSGENICS;

BRAIN; GLYCOPROTEINS; MAMMALS; NEURODEGENERATIVE DISEASES;

PROTEINS;

POLYGLUTAMINE;

ACCURACY; ALZHEIMER DISEASE; AMYLOID SEEDING ASSAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CADAVER; CELL INCLUSION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PREDICTION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN UNFOLDING; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; INCLUSION BODIES; MICE; MICE, TRANSGENIC; PEPTIDES; PRION DISEASES; PROTEIN FOLDING;

MUS; MUS MUSCULUS;

EID: 84858964576     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.305417     Document Type: Article

References (48)

1. Huntington, G. (1872) On chorea. Med. Surg. Rep. 26, 317-321
2. The Huntington Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington disease chromosomes. Cell 72, 971-983
3. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (Pubitemid 27449140)
4. Gourfinkel-An, I., Cancel, G., Duyckaerts, C., Faucheux, B., Hauw, J. J., Trottier, Y., Brice, A., Agid, Y., and Hirsch, E. C. (1998) Neuronal distribution of intranuclear inclusions in Huntington disease with adult onset. Neuroreport 9, 1823-1826 (Pubitemid 28289192)
5. Herndon, E. S., Hladik, C. L., Shang, P., Burns, D. K., Raisanen, J., and White, C. L. (2009) Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. J. Neuropathol. Exp. Neurol. 68, 250-261
6. Maat-Schieman, M., Roos, R., Losekoot, M., Dorsman, J., Welling-Graafland, C., Hegeman-Kleinn, I., Broeyer, F., Breuning, M., and van Duinen, S. (2007) Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington disease. Brain Pathol. 17, 31-37
7. Sieradzan, K. A., Mechan, A. O., Jones, L., Wanker, E. E., Nukina, N., and Mann, D. M. (1999) Huntington disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol. 156, 92-99 (Pubitemid 29152986)
8. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M. E. (1998) Huntingtin acts in the nucleus to induce apoptosis, but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66
9. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., and Finkbeiner, S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (Pubitemid 39434070)
10. Yang, W., Dunlap, J. R., Andrews, R. B., and Wetzel, R. (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917
11. Campioni, S., Mannini, B., Zampagni, M., Pensalfini, A., Parrini, C., Evangelisti, E., Relini, A., Stefani, M., Dobson, C. M., Cecchi, C., and Chiti, F. (2010) A causative link between the structure of aberrant protein oligomers and their toxicity. Nat. Chem. Biol. 6, 140-147
12. Nucifora, F. C., Jr., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2001) Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 291, 2423-2428 (Pubitemid 32231807)
13. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., and Bates, G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (Pubitemid 26374323)
14. Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., and Bates, G. P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 (Pubitemid 27347243)
15. Dedeoglu, A., Kubilus, J. K., Jeitner, T. M., Matson, S. A., Bogdanov, M., Kowall, N. W., Matson, W. R., Cooper, A. J., Ratan, R. R., Beal, M. F., Hersch, S. M., and Ferrante, R. J. (2002) Therapeutic effects of cystamine in a murine model of Huntington disease. J. Neurosci. 22, 8942-8950 (Pubitemid 35379064)
16. DeMarch, Z., Giampà, C., Patassini, S., Bernardi, G., and Fusco, F. R. (2008) Beneficial effects of rolipram in the R6/2 mouse model of Huntington disease. Neurobiol. Dis. 30, 375-387
17. Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., and Beal, M. F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington disease. J. Neurosci. 20, 4389-4397 (Pubitemid 30396603)
18. Li, H., Li, S. H., Cheng, A. L., Mangiarini, L., Bates, G. P., and Li, X. J. (1999) Ultrastructural localization and progressive formation of neuropil aggregates in Huntington disease transgenic mice. Hum. Mol. Genet. 8, 1227-1236 (Pubitemid 29328991)
19. Simmons, D. A., Mehta, R. A., Lauterborn, J. C., Gall, C. M., and Lynch, G. (2011) Brief ampakine treatments slow the progression of Huntington disease phenotypes in R6/2 mice. Neurobiol. Dis. 41, 436-444
20. Schilling, G., Becher, M. W., Sharp, A. H., Jinnah, H. A., Duan, K., Kotzuk, J. A., Slunt, H. H., Ratovitski, T., Cooper, J. K., Jenkins, N. A., Copeland, N. G., Price, D. L., Ross, C. A., and Borchelt, D. R. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407 (Pubitemid 29097327)
21. Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., Hersch, S. M., Ross, C. A., and Beal, M. F. (2001) Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington disease. Neurobiol. Dis. 8, 479-491 (Pubitemid 32566138)
22. Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., and Davidson, B. L. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 102, 5820-5825 (Pubitemid 40559643)
23. Masuda, N., Peng, Q., Li, Q., Jiang, M., Liang, Y., Wang, X., Zhao, M., Wang, W., Ross, C. A., and Duan, W. (2008) Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington disease. Neurobiol. Dis. 30, 293-302
24. Zádori, D., Nyiri, G., Szonyi, A., Szatmári, I., Fülöp, F., Toldi, J., Freund, T. F., Vécsei, L., and Klivényi, P. (2011) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington disease. J. Neural Transm. 118, 865-875
25. Hodgson, J. G., Agopyan, N., Gutekunst, C. A., Leavitt, B. R., LePiane, F., Singaraja, R., Smith, D. J., Bissada, N., McCutcheon, K., Nasir, J., Jamot, L., Li, X. J., Stevens, M. E., Rosemond, E., Roder, J. C., Phillips, A. G., Rubin, E. M., Hersch, S. M., and Hayden, M. R. (1999) A YAC mouse model for Huntington disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23, 181-192 (Pubitemid 29262475)
26. Slow, E. J., van Raamsdonk, J., Rogers, D., Coleman, S. H., Graham, R. K., Deng, Y., Oh, R., Bissada, N., Hossain, S. M., Yang, Y. Z., Li, X. J., Simpson, E. M., Gutekunst, C. A., Leavitt, B. R., and Hayden, M. R. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12, 1555-1567 (Pubitemid 36857303)
27. Van Raamsdonk, J. M., Pearson, J., Slow, E. J., Hossain, S. M., Leavitt, B. R., and Hayden, M. R. (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington disease. J. Neurosci. 25, 4169-4180 (Pubitemid 40563393)
28. Crook, Z. R., and Housman, D. (2011) Huntington's disease: can mice lead the way to treatment? Neuron 69, 423-435
29. Van Raamsdonk, J. M., Metzler, M., Slow, E., Pearson, J., Schwab, C., Carroll, J., Graham, R. K., Leavitt, B. R., and Hayden, M. R. (2007) Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis. 26, 189-200 (Pubitemid 46436497)
30. Colby, D. W., Zhang, Q., Wang, S., Groth, D., Legname, G., Riesner, D., and Prusiner, S. B. (2007) Prion detection by an amyloid seeding assay. Proc. Natl. Acad. Sci. U.S.A. 104, 20914-20919
31. Du, D., Murray, A. N., Cohen, E., Kim, H. E., Simkovsky, R., Dillin, A., and Kelly, J. W. (2011) A kinetic aggregation assay allowing selective and sensitive amyloid-β quantification in cells and tissues. Biochemistry 50, 1607-1617
32. Saeed, S. M., and Fine, G. (1967) Thioflavin T for amyloid detection. Am. J. Clin. Pathol. 47, 588-593
33. Wilham, J. M., Orru, C. D., Bessen, R. A., Atarashi, R., Sano, K., Race, B., Meade-White, K. D., Taubner, L. M., Timmes, A., and Caughey, B. (2010) Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog. e1001217
34. Atarashi, R., Satoh, K., Sano, K., Fuse, T., Yamaguchi, N., Ishibashi, D., Matsubara, T., Nakagaki, T., Yamanaka, H., Shirabe, S., Yamada, M., Mizusawa, H., Kitamoto, T., Klug, G., McGlade, A., Collins, S. J., and Nishida, N. (2011) Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat. Med. 17, 175-178
35. Colby, D. W., Wain, R., Baskakov, I. V., Legname, G., Palmer, C. G., Nguyen, H. O. B., Lemus, A., Cohen, F. E., DeArmond, S. J., and Prusiner, S. B. (2010) Protease-sensitive synthetic prions. PLoS Pathog. e1000736
36. Nekooki-Machida, Y., Kurosawa, M., Nukina, N., Ito, K., Oda, T., and Tanaka, M. (2009) Distinct conformations of in vitro and in vivo amyloids of huntingtin exon 1 show different cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 106, 9679-9684
37. O'Nuallain, B., Thakur, A. K., Williams, A. D., Bhattacharyya, A. M., Chen, S., Thiagarajan, G., and Wetzel, R. (2006) Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay. Methods Enzymol. 413, 34-74 (Pubitemid 44528684)
38. Díaz-Hernández, M., Moreno-Herrero, F., Gómez-Ramos, P., Morán, M. A., Ferrer, I., Baró, A. M., Avila, J., Hernández, F., and Lucas, J. J. (2004) Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J. Neurosci. 24, 9361-9371 (Pubitemid 39426173)
39. Chen, S., Berthelier, V., Yang, W., and Wetzel, R. (2001) Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173-182 (Pubitemid 32735322)
40. Chen, S., Ferrone, F. A., and Wetzel, R. (2002) Huntington disease age of onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad.Sci. U.S.A. 99, 11884-11889 (Pubitemid 34994493)
41. Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., and Wanker, E. E. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558 (Pubitemid 27347244)
42. Schilling, G., Jinnah, H. A., Gonzales, V., Coonfield, M. L., Kim, Y., Wood, J. D., Price, D. L., Li, X. J., Jenkins, N., Copeland, N., Moran, T., Ross, C. A., and Borchelt, D. R. (2001) Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. Neurobiol. Dis. 8, 405-418 (Pubitemid 32566132)
43. Van Raamsdonk, J. M., Murphy, Z., Slow, E. J., Leavitt, B. R., and Hayden, M. R. (2005) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14, 3823-3835 (Pubitemid 43020084)
44. Wheeler, V. C., White, J. K., Gutekunst, C. A., Vrbanac, V., Weaver, M., Li, X. J., Li, S. H., Yi, H., Vonsattel, J. P., Gusella, J. F., Hersch, S., Auerbach, W., Joyner, A. L., and MacDonald, M. E. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 9, 503-513 (Pubitemid 30154008)
45. Menalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S., and Chesselet, M. F. (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 465, 11-26 (Pubitemid 37075677)
46. Legleiter, J., Mitchell, E., Lotz, G. P., Sapp, E., Ng, C., DiFiglia, M., Thompson, L. M., and Muchowski, P. J. (2010) Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J. Biol. Chem. 285, 14777-14790
47. Colby, D. W., Cassady, J. P., Lin, G. C., Ingram, V. M., and Wittrup, K. D. (2006) Stochastic kinetics of intracellular huntingtin aggregate formation. Nat. Chem. Biol. 2, 319-323 (Pubitemid 43787213)
48. Colby, D. W., Chu, Y., Cassady, J. P., Duennwald, M., Zazulak, H., Webster, J. M., Messer, A., Lindquist, S., Ingram, V. M., and Wittrup, K. D. (2004) Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. U.S.A. 101, 17616-17621 (Pubitemid 40051935)